clofarabine has been researched along with alvocidib in 6 studies
| Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) | Studies (alvocidib) | Trials (alvocidib) | Recent Studies (post-2010) (alvocidib) |
|---|---|---|---|---|---|
| 424 | 101 | 280 | 627 | 66 | 204 |
| Protein | Taxonomy | clofarabine (IC50) | alvocidib (IC50) |
|---|---|---|---|
| Chain A, Protein (glycogen Phosphorylase) | Oryctolagus cuniculus (rabbit) | 1 | |
| Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 0.36 | |
| [Tau protein] kinase | Sus scrofa (pig) | 0.36 | |
| Cyclin-T1 | Homo sapiens (human) | 0.0243 | |
| Cyclin-K | Homo sapiens (human) | 1.37 | |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | 8 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.1571 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.36 | |
| Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | 1.2 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 7.6 | |
| Vitamin K-dependent protein C | Homo sapiens (human) | 0.1429 | |
| Protein kinase C gamma type | Homo sapiens (human) | 8 | |
| Protein kinase C beta type | Homo sapiens (human) | 8 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.4 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.1159 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.1589 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.1464 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.2067 | |
| Protein kinase C alpha type | Homo sapiens (human) | 6.2667 | |
| Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | 0.185 | |
| Cyclin-A2 | Homo sapiens (human) | 0.3441 | |
| Dual specificity protein kinase CLK1 | Mus musculus (house mouse) | 1.3 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.1837 | |
| Protein kinase C eta type | Homo sapiens (human) | 8 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.2249 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.2367 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.1 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.1983 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.4 | |
| Protein kinase C iota type | Homo sapiens (human) | 8 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.525 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.6517 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.3365 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0209 | |
| Cyclin-H | Homo sapiens (human) | 0.3413 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.514 | |
| Cyclin-A1 | Homo sapiens (human) | 0.785 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.1572 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.1747 | |
| Cyclin homolog | Herpesvirus saimiri (strain 11) | 0.185 | |
| Protein kinase C epsilon type | Homo sapiens (human) | 5.4933 | |
| Protein kinase C theta type | Homo sapiens (human) | 8 | |
| Protein kinase C zeta type | Homo sapiens (human) | 8 | |
| Protein kinase C delta type | Homo sapiens (human) | 5.63 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.1765 | |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | 8 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Rattus norvegicus (Norway rat) | 0.3 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.1571 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.2067 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 1.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cheson, BD | 1 |
| Beesley, AH; Cummings, AJ; de Klerk, NH; Firth, MJ; Ford, J; Freitas, JR; Kees, UR; Palmer, ML; Perera, KU; Weller, RE | 1 |
| Bolaños-Meade, J; Villela, L | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Hosono, N; Negoro, E; Nishi, R; Okura, M; Shigemi, H; Yamauchi, T | 1 |
2 review(s) available for clofarabine and alvocidib
| Article | Year |
|---|---|
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Acute myeloid leukaemia: optimal management and recent developments.
Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Daunorubicin; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines | 2011 |
4 other study(ies) available for clofarabine and alvocidib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Burkitt Lymphoma; Child; Clofarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flavonoids; Humans; Inhibitory Concentration 50; Leukemia-Lymphoma, Adult T-Cell; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 2007 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Clofarabine; Cytarabine; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines; Sulfonamides | 2020 |